Your SlideShare is downloading. ×
0
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Final M&A 2003
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Final M&A 2003

1,157

Published on

7ppts on M&A wth example of ranbaxy

7ppts on M&A wth example of ranbaxy

Published in: Business, Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,157
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
82
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1.
  • 2. Incentives for Mergers and Acquisitions by Indian companies<br /><ul><li>Build critical mass in terms of marketing, manufacturing and research infrastructure
  • 3. Establish front end presence
  • 4. Diversification into new areas
  • 5. Enhance product, technology and intellectual property portfolio
  • 6. Catapulting market share</li></li></ul><li>
  • 7.
  • 8. About Ranbaxy <br /><ul><li>Incorporated in 1961
  • 9. Came with IPO in 1973
  • 10. Global footprint in 49 countries
  • 11. World-class manufacturing facilities in 11 countries
  • 12. Serves customers in over 125 countries</li></li></ul><li>
  • 13.
  • 14.
  • 15. <ul><li>Acquired 34.8% promoter stake of Ranbaxy at a price of Rs.737 per share
  • 16. Transaction value = US$ 4.6 billion (Rs.19780 crores.)</li></ul> (Currency Exchange Rate 1US$ = Rs.43)<br /><ul><li>Financed through a mix of bank debt facilities and existing cash resources of Daiichi Sankyo</li></ul>About the deal<br />
  • 17. About the deal<br /><ul><li>Total no. of shares acquired : 220.6 million
  • 18. Through open offer : 92.5 million
  • 19. From the promoter : 81.9 million
  • 20. Through the preferential issue </li></ul> of equity shares and warrants 46.2 million <br />
  • 21. Benefits to Daiichi Sankyo Ltd. <br /><ul><li>Ranbaxy’s:</li></ul> low-cost manufacturing infrastructure and <br /> supply chain strengths<br /><ul><li>Elevate the Daiichi Sankyo’s position from 22 to 15 by market capitalization in the global pharmaceutical market. </li></li></ul><li>Benefits to Ranbaxy Ltd.<br /><ul><li>Ranbaxy gains access to Daiichi Sankyo’s research and development expertise to advance its branded drugs business.
  • 22. The deal frees up its debt and imparts more flexibility into its growth plans.</li></li></ul><li>SYNERGY<br />
  • 23. Long-term value for all stakeholders<br /><ul><li>A complementary business combination
  • 24. An expanded global reach
  • 25. Strong growth potential
  • 26. Cost competitiveness</li></li></ul><li>
  • 27.
  • 28. REFERENCES<br />Research report by Daiichi Sankyo Ltd.<br />Economic Times dated 12th June, 2008.<br />The Financial Express dated 21st Oct.,2008.<br />

×